Article
Cardiac & Cardiovascular Systems
Daigo Takahashi, Hideki Wada, Manabu Ogita, Kentaro Yasuda, Ryota Nishio, Mitsuhiro Takeuchi, Jun Shitara, Shuta Tsuboi, Tomotaka Dohi, Satoru Suwa, Katsumi Miyauchi, Hiroyuki Daida, Tohru Minamino
Summary: This study evaluated the impact of Lp(a) levels on long-term cardiovascular outcomes in ACS patients treated with statins. It found that high Lp(a) levels were significantly associated with a higher risk of MACE, suggesting that Lp(a) could be a potential biomarker for predicting residual risk of future clinical events.
AMERICAN JOURNAL OF CARDIOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Seung-Jun Lee, Jung-Joon Cha, Woong Gil Choi, Wang-Soo Lee, Jin-Ok Jeong, Seonghoon Choi, Yoon-Haeng Cho, Woojung Park, Chang-Hwan Yoon, Yong-Joon Lee, Sung-Jin Hong, Chul-Min Ahn, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang, Soon Jun Hong, Jung-Sun Kim, RACING Investigators
Summary: The study aimed to evaluate the outcomes of a moderate-intensity statin with ezetimibe combination in patients with high-risk and non-high-risk atherosclerotic cardiovascular disease (ASCVD). The results showed that there was no significant difference in the primary endpoint between combination therapy and high-intensity statin monotherapy in both VHR and non-VHR patients. Furthermore, the combination therapy reduced low-density lipoprotein cholesterol levels and decreased the occurrence of drug intolerance.
Article
Cardiac & Cardiovascular Systems
Yong-Joon Lee, Jae Young Cho, Seng Chan You, Yong-Ho Lee, Kyeong Ho Yun, Yun-Hyeong Cho, Won-Yong Shin, Sang Wook Im, Woong Chol Kang, Yongwhi Park, Sung Yoon Lee, Seung-Jun Lee, Sung-Jin Hong, Chul-Min Ahn, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang, Jung-Sun Kim
Summary: This study evaluated the effect of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy among patients with diabetes mellitus and atherosclerotic cardiovascular disease. The study found that the combination therapy had similar outcomes in terms of cardiovascular events compared to the monotherapy, but had a higher rate of intolerance-related discontinuation or dose reduction. However, the combination therapy was more effective in achieving lower LDL cholesterol levels.
EUROPEAN HEART JOURNAL
(2023)
Article
Cardiac & Cardiovascular Systems
Leonardo De Luca, Pier Luigi Temporelli, Michele Massimo Gulizia, Lucio Gonzini, Tiziana Anita Ammaturo, Luigi Tedesco, Silvia Pede, Fabrizio Oliva, Domenico Gabrielli, Furio Colivicchi, Maurizio R. Averna
Summary: This study evaluated the predictive role of hypertriglyceridemia in patients with chronic coronary syndromes treated with statins, but found that elevated triglyceride levels were not an independent predictor of major adverse cardio-cerebrovascular events at 1 year.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
(2023)
Article
Cardiac & Cardiovascular Systems
Sang-Hyup Lee, Yong -Joon Lee, Jung Ho Heo, Seung-Ho Hur, Hyun Hee Choi, Kyung-Jin Kim, Ju Han Kim, Keun-Ho Park, Jung Hee Lee, Yu Jeong Choi, Seung-Jun Lee, Sung-Jin Hong, Chul-Min Ahn, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang, Jung-Sun Kim
Summary: This study compared the cardiovascular effects and tolerability of combination therapy with moderate-intensity statins and ezetimibe versus high-intensity statin monotherapy in elderly patients. The results showed no significant difference in the occurrence of cardiovascular events between the two treatment groups among patients aged ≥75 years and <75 years, but the combination therapy group had lower rates of adverse reactions. Therefore, combination therapy with moderate-intensity statins and ezetimibe has similar cardiovascular effects and greater tolerability in elderly patients.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Seung-Jun Lee, Jung-Joon Cha, Woong Gil Choi, Wang-Soo Lee, Jin-Ok Jeong, Seonghoon Choi, Yoon-Haeng Cho, Woojung Park, Chang-Hwan Yoon, Yong-Joon Lee, Sung-Jin Hong, Chul-Min Ahn, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang, Soon Jun Hong, Jung-Sun Kim
Summary: The study aimed to evaluate the outcomes of a moderate-intensity statin with ezetimibe combination in patients with very high risk (VHR) and non-VHR of atherosclerotic cardiovascular disease (ASCVD). The results showed no significant difference in the primary end point between combination therapy and high-intensity statin monotherapy in both VHR and non-VHR patients. Additionally, the combination therapy group had significantly lower levels of low-density lipoprotein cholesterol (LDL-C) compared to the high-intensity statin group, and was associated with greater changes in LDL-C levels and a higher proportion of patients with LDL-C levels below 70 mg/dL. The discontinuation or dose reduction of lipid-lowering drugs due to intolerance occurred less frequently in the combination therapy group.
Article
Cardiac & Cardiovascular Systems
Natalie C. Ward, Christopher M. Reid, Gerald F. Watts
Summary: This study found that nutraceuticals and ezetimibe independently or in combination can lower LDL-c in patients with hypercholesterolemia who are intolerant to statins.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Multidisciplinary Sciences
Jihaeng Im, Erisa Kawada-Watanabe, Junichi Yamaguchi, Hiroyuki Arashi, Hisao Otsuki, Yuko Matsui, Haruki Sekiguchi, Shinya Fujii, Fumiaki Mori, Hiroshi Ogawa, Nobuhisa Hagiwara
Summary: The study evaluated the impact of baseline low-density lipoprotein cholesterol on the outcomes of acute coronary syndrome patients receiving different statin therapies. The results indicated that patients with low LDL-C levels did not benefit from combination therapy, while those with high LDL-C levels showed better clinical results with combination therapy compared to monotherapy.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
April K. S. Salama, Manisha Palta, Christel N. Rushing, M. Angelica Selim, Kristen N. Linney, Brian G. Czito, David S. Yoo, Brent A. Hanks, Georgia M. Beasley, Paul J. Mosca, Chelsae Dumbauld, Katelyn N. Steadman, John S. Yi, Kent J. Weinhold, Douglas S. Tyler, Walter T. Lee, David M. Brizel
Summary: This study demonstrated the feasibility of concurrent administration of ipilimumab and radiation as adjuvant, neoadjuvant, or definitive therapy in patients with regionally advanced melanoma, resulting in high response rates and improved survival outcomes. Further research on the combination of radiation and checkpoint inhibitor therapy is warranted.
CLINICAL CANCER RESEARCH
(2021)
Article
Medicine, General & Internal
Byeong-Keuk Kim, Sung-Jin Hong, Yong-Joon Lee, Soon Jun Hong, Kyeong Ho Yun, Bum-Kee Hong, Jung Ho Heo, Seung-Woon Rha, Yun-Hyeong Cho, Seung-Jun Lee, Chul-Min Ahn, Jung-Sun Kim, Young-Guk Ko, Donghoon Choi, Yangsoo Jang, Myeong-Ki Hong
Summary: Through a randomized trial, it was found that the combination therapy of moderate-intensity statin and ezetimibe is as effective as high-intensity statin monotherapy in reducing cardiovascular events and maintaining stable LDL cholesterol concentrations, with better drug tolerance.
Article
Cardiac & Cardiovascular Systems
Joanna Lewek, Jacek Niedziela, Piotr Desperak, Krzysztof Dyrbus, Tadeusz Osadnik, Piotr Jankowski, Adam Witkowski, Agata Bielecka-Dabrowa, Dariusz Dudek, Marek Gierlotka, Mariusz Gasior, Maciej Banach
Summary: Compared to statin monotherapy, upfront combination therapy of statin and ezetimibe significantly reduces all-cause mortality in patients with acute coronary syndromes.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2023)
Article
Cardiac & Cardiovascular Systems
Michel Farnier, Raul D. Santos, Juan Cosin-Sales, Marat Ezhov, Jian Liu, Denis Granados, Serena Santoni, Irfan Khan, Alberico L. Catapano
Summary: According to the 2019 ESC/EAS guidelines, the use of statin, ezetimibe, and statin plus ezetimibe FDC treatment strategies can significantly reduce the incidence of major adverse cardiovascular events at the population level.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2022)
Article
Endocrinology & Metabolism
Yong-Joon Lee, Sang-Hyup Lee, Seng Chan You, Yong-ho Lee, Seung-Jun Lee, Sung-Jin Hong, Chul-Min Ahn, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang, Jung-Sun Kim
Summary: The study evaluated the safety and efficacy of a moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with metabolic syndrome (MetS) and atherosclerotic cardiovascular disease. The combination therapy showed comparable cardiovascular benefits with lower drug intolerance and low-density lipoprotein cholesterol levels compared to monotherapy, but no significant difference in new-onset diabetes.
DIABETES OBESITY & METABOLISM
(2023)
Article
Cardiac & Cardiovascular Systems
Julius L. Katzmann, Francesc Sorio-Vilela, Eugen Dornstauder, Uwe Fraas, Timo Smieszek, Sofia Zappacosta, Ulrich Laufs
Summary: Many patients with high cardiovascular disease risk do not achieve the recommended LDL-C targets. Prescription trends for non-statin lipid-lowering therapies have increased in Germany, but are infrequent among general practitioners. Combination therapy with fixed-dose combinations leads to greater reduction in LDL-C, but a significant proportion of patients still have uncontrolled LDL-C levels.
CLINICAL RESEARCH IN CARDIOLOGY
(2022)
Review
Medicine, General & Internal
Safi U. Khan, Siva H. Yedlapati, Ahmad N. Lone, Qiukui Hao, Gordon Guyatt, Nicolas Delvaux, Geertruida E. (Trudy) Bekkering, Per Olav Vandvik, Irbaz Bin Riaz, Sheyu Li, Bert Aertgeerts, Nicolas Rodondi
Summary: This study aims to compare the impact of ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on cardiovascular outcomes in adults taking maximally tolerated statin therapy or who are statin intolerant.
BMJ-BRITISH MEDICAL JOURNAL
(2022)
